CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

What this study is about

The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.

Who can join (things the study team will check)

✅ You may be able to join if…

• >18 years of age
• Patient or primary caregiver can read and speak English
• Patient or patients substitute decision maker is able to provide informed consent
• Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.)
• Have stage 5 CKD (2 measurements of eGFR <15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation, or have >40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation
• Followed in a multidisciplinary CKD clinic

🚫 You may not be able to join if…

• Inability of self or caregiver assisted self-monitoring using VIEWER

Where this trial is running

• St. Boniface Hospital, Winnipeg, Manitoba, Canada
• Chronic Disease Innovation Centre, Seven Oaks Hospital, Winnipeg, Manitoba, Canada
• Health Sciences Centre, Winnipeg, Manitoba, Canada
• London Health Sciences Centre, London, Ontario, Canada
• Scarborough Health Network - General Hospital, Scarborough Village, Ontario, Canada

Who to contact

Claudio Rigatto, MD · 204-631-3834 · crigatto@sogh.mb.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05726526.